Concord Biotech Past Earnings Performance
Past criteria checks 6/6
Concord Biotech has been growing earnings at an average annual rate of 13.1%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 15.8% per year. Concord Biotech's return on equity is 20.2%, and it has net margins of 30.3%.
Key information
13.1%
Earnings growth rate
13.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 15.8% |
| Return on equity | 20.2% |
| Net Margin | 30.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Concord Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 10,169 | 3,081 | 1,231 | 0 |
| 31 Dec 23 | 9,706 | 3,046 | 1,178 | 0 |
| 30 Sep 23 | 9,704 | 3,044 | 1,147 | 0 |
| 30 Jun 23 | 8,670 | 2,453 | 1,134 | 0 |
| 31 Mar 23 | 8,532 | 2,401 | 1,103 | 0 |
| 31 Mar 22 | 7,129 | 1,749 | 957 | 0 |
| 31 Mar 21 | 6,169 | 2,349 | 700 | 0 |
| 31 Mar 20 | 5,123 | 1,691 | 624 | 0 |
Quality Earnings: 543960 has high quality earnings.
Growing Profit Margin: 543960's current net profit margins (30.3%) are higher than last year (28.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 543960's earnings have grown by 13.1% per year over the past 5 years.
Accelerating Growth: 543960's earnings growth over the past year (28.3%) exceeds its 5-year average (13.1% per year).
Earnings vs Industry: 543960 earnings growth over the past year (28.3%) exceeded the Pharmaceuticals industry 18.2%.
Return on Equity
High ROE: 543960's Return on Equity (20.2%) is considered high.